{"id":3600,"date":"2021-10-13T15:08:50","date_gmt":"2021-10-13T15:08:50","guid":{"rendered":"https:\/\/mirm-pitt.net\/technologies\/?post_type=avada_portfolio&p=3600"},"modified":"2021-10-13T15:08:50","modified_gmt":"2021-10-13T15:08:50","slug":"methods-for-diagnosing-prostate-cancer-and-predicting-prostate-cancer-relapse-2","status":"publish","type":"avada_portfolio","link":"https:\/\/mirm-pitt.net\/technologies\/patents\/methods-for-diagnosing-prostate-cancer-and-predicting-prostate-cancer-relapse-2\/","title":{"rendered":"Methods for diagnosing prostate cancer and predicting prostate cancer relapse"},"content":{"rendered":"

Methods for diagnosing prostate cancer and predicting prostate cancer relapse<\/h2>\n
\n
\n
\n

<\/h2>\n<\/section>\n<\/div>\n<\/div>\n<\/div>
<\/div><\/div><\/div>

Inventors: <\/strong>Jianhua Luo, George Konstantine Michalopoulos, Joel B. Nelson, Chi Song, Chien-Cheng Tseng, Yanping Yu<\/p>\n

Patent Number: <\/strong>US10760132B2<\/p>\n

\n
\n
\n

Abstract<\/h3>\n
\n
\n
The present invention relates to methods and compositions for diagnosing prostate cancer and\/or determining whether a prostate cancer patient is at increased risk of suffering a relapse, or a rapid relapse, of his cancer. It is based, at least in part, on the results of a comprehensive genome analysis on 241 prostate cancer samples (104 prostate cancer, 85 matched bloods, 49 matched benign prostate tissues adjacent to cancer, and 3 cell lines) which indicate that (i) genome copy number variation (CNV) occurred in both cancer and non-cancer tissues, and (ii) CNV predicts prostate cancer progression.<\/div>\n<\/section>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<\/div>
<\/div>
<\/div>
<\/div>